Welcome to our dedicated page for Surrozen SEC filings (Ticker: SRZNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Surrozen, Inc. (SRZNW for its warrants and SRZN for its common stock) files reports and disclosure documents with the U.S. Securities and Exchange Commission as a public biotechnology company in the biological product manufacturing industry. This SEC filings page brings together those documents so users can review how Surrozen describes its business, capital structure, and material events in official regulatory submissions.
Surrozen’s filings include Form 8-K current reports that outline significant corporate developments. For example, one Form 8-K describes a Sales Agreement with TD Securities (USA) LLC (TD Cowen) that allows Surrozen to offer and sell shares of its common stock in at-the-market offerings under a Form S-3 registration statement. The filing explains that TD Cowen may sell shares on the Nasdaq Capital Market or other existing trading markets, and that Surrozen will pay a commission on gross sales proceeds and provide customary indemnification.
Another Form 8-K details the issuance of a press release announcing Surrozen’s financial results for a specific quarter, categorized under "Results of Operations and Financial Condition." In that report, the company notes that the information, including the press release exhibit, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Such filings help readers understand how Surrozen reports its operating performance and significant events.
On this page, users can access Surrozen’s SEC filings as they are made available through EDGAR, including current reports like Form 8-K, registration statements such as Form S-3, and related exhibits. AI-powered summaries can assist in interpreting key sections, such as descriptions of capital-raising arrangements, warrant and common stock references, and other disclosures about Surrozen’s Wnt pathway-focused biotechnology business.
Surrozen, Inc. executive Li Yang received new equity awards consisting of stock options and restricted stock units. On February 17, 2026, Yang was granted options to purchase 100,950 shares of common stock at an exercise price of $0.00 per share and 100,950 restricted stock units.
The stock options vest over four years in 48 equal monthly installments starting February 1, 2026, conditioned on continued service. The RSUs vest in four equal annual installments beginning February 1, 2026, also subject to continued service. These awards represent direct ownership incentives rather than open-market share purchases.
Williams Charles O reported acquisition or exercise transactions in this Form 4 filing.
Surrozen, Inc. reported that its Chief Operating Officer, Charles O. Williams, received two new equity awards. On February 17, 2026, he was granted employee stock options covering 102,900 shares of common stock at a grant price of $0.00 per share. These option shares vest over four years in 48 equal monthly installments starting February 1, 2026, conditioned on continued service. He was also granted 102,900 restricted stock units, each representing one share of common stock, which vest in four equal annual installments beginning February 1, 2026, also subject to continued service.
Surrozen, Inc. reported that Chief Executive Officer Craig C. Parker received new equity awards. On February 17, 2026, he was granted an employee stock option covering 242,200 shares of common stock at an exercise price of
The option vests over four years in 48 equal monthly installments starting from
Braidwell and affiliates disclosed a significant position in Surrozen, Inc. common stock. As of December 31, 2025, Braidwell LP, Braidwell Management LLC, Alexander T. Karnal, and Brian J. Kreiter may be deemed beneficial owners of 470,000 shares, representing about 5.5% of Surrozen’s outstanding common stock.
All 470,000 shares are directly owned by Braidwell Partners Master Fund LP, with each reporting person sharing voting and dispositive power and no sole authority. The stake is reported as being held in the ordinary course of business and not for the purpose of changing or influencing control of Surrozen.
Surrozen, Inc. received an updated ownership report showing that RA Capital Management, its affiliated fund, and principals Peter Kolchinsky and Rajeev Shah collectively report beneficial ownership of 871,731 shares of common stock, representing 9.2% of the class as of December 31, 2025.
The position includes Series A warrants for up to 322,580 shares, Series B warrants for up to 350,876 shares, and Series E warrants for up to 198,275 shares of common stock. The filing states the securities are not held for the purpose of changing or influencing control of Surrozen.
StemPoint Capital and related parties reported a significant ownership stake in Surrozen, Inc. The Schedule 13G/A shows StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross collectively beneficially owning 619,766 shares of Surrozen common stock, including 329,658 shares issuable upon exercise of warrants.
This represents 7.0% of Surrozen’s common stock, calculated using 8,571,421 shares outstanding as of November 5, 2025, plus specified Series A, B, and E warrants subject to a 9.9% beneficial ownership limitation. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Surrozen.
Stonepine Capital Management, Stonepine Capital, Stonepine GP and Jon M. Plexico filed an amended Schedule 13G reporting beneficial ownership of 316,289 shares of Surrozen, Inc. common stock, representing 3.6% of the class as of the reported date.
The stake consists of 113,631 shares of common stock plus 202,658 shares issuable upon exercise of Series A, Series B and Series E warrants, all subject to a 9.9% beneficial ownership limitation. The percentage is based on 8,571,421 shares outstanding as of November 5, 2025, and the filers certify the holdings are not for the purpose of changing or influencing control.
TCG Crossover investment entities increased their indirect stake in Surrozen, Inc. common stock through open-market purchases. On February 11, 2026, TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P. each bought 8,882 and 8,881 shares at $23.575 per share, respectively. On February 12, 2026, they bought additional blocks of 547 and 546 shares at $23.8625 per share. After these transactions, one fund reported beneficial ownership of 651,114 shares and the other 651,112 shares, all held indirectly through the TCG Crossover fund structure.
TCG Crossover investment entities reported open-market purchases of Surrozen, Inc. (SRZN) common stock. On January 30, 2026, TCG Crossover Fund II, L.P. bought 2,136 shares at
On February 2, 2026, Fund II purchased 366 shares at
TCG Crossover funds and Chen Yu report significant ownership in Surrozen, Inc. common stock. TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P., through their general partners, each report beneficial ownership of 637,005 shares, or 5.7% of Surrozen’s common stock.
Chen Yu, as sole managing member of both general partners, reports beneficial ownership of 1,274,010 shares, representing 11.4% of the outstanding common stock based on 11,191,978 shares outstanding as of January 27, 2026. The filing states the securities were not acquired or held for the purpose of changing or influencing control of Surrozen.